Showing results (361-370 of 483) with videos related to

Sort By:
Pageof 49
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaJoerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.
Nature Communications|February 12, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaStephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
EJNMMI Research|April 5, 2024
Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysisCristina E Popescu, Boya Zhang, Thomas Sartoretti, et al.
The Lancet. Oncology|December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Pageof 49